Much has been written about the ethics of experimental research upon human subjects, particularly where such subjects can be said to be in a vulnerable position in relation to the researcher. This paper attempts to address such questions with reference to people who are dying. A case is made to defend the view that no research is morally justifiable with this client group. Less extreme views are also explored. One justification for such research activity comes from a rights-based perspective and another from the weighing of benefits and harms. In the process of exploring these issues, the author attempts to demonstrate that no research methodology can be said to be benign.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/026921639400800405 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A taxonomy of the factors contributing to the overtreatment of cancer patients at the end of life. What is the problem? Why does it happen? How can it be addressed?
ESMO Open
January 2025
Office of Quality and Value, The University of Texas MD Anderson Cancer Center, Houston, USA.
Many patients with cancer approaching the end of life (EOL) continue to receive treatments that are unlikely to provide meaningful clinical benefit, potentially causing more harm than good. This is called overtreatment at the EOL. Overtreatment harms patients by causing side-effects, increasing health care costs, delaying important discussions about and preparation for EOL care, and occasionally accelerating death.
View Article and Find Full Text PDFConsanguinity and hearing loss prevalence among Saudi Arabia population.
Int J Pediatr Otorhinolaryngol
December 2024
Department of Otolaryngology-Head and Neck Surgery, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh, Saudi Arabia. Electronic address:
Background: Childhood hearing loss (CHL) is a condition that can have a variety of causes, including genetic and environmental and its prevalence is thought to be high in Saudi Arabian population mainly due to consanguineous unions. This systematic literature review aims to conclude the prevalence of hereditary hearing loss and its risk factors among the Saudi population.
Methods: In September 2023, a thorough search was performed on the PubMed, CENTRAL, MEDLINE, and EMBASE databases.
Predatory journals: What can we do to protect their prey?
Medwave
January 2025
Editor-in-Chief, La Tunisie Médicale.
Eugene Hertoghe (1860-1928): Pioneer in endocrinology and the treatment of hypothyroidism.
J Med Biogr
January 2025
Department of Medicine, University of Central Florida College of Medicine, Orlando, FL, USA.
Eugène Hertoghe (1860-1928), a Belgian internist and former vice-president of the Royal Academy of Medicine of Belgium, made significant contributions to the understanding and treatment of chronic hypothyroidism. He provided a detailed clinical description of the condition, emphasizing its multisystemic manifestations and hereditary aspects. Hertoghe also documented the therapeutic use of thyroid extract, reporting its effectiveness in alleviating symptoms of hypothyroidism.
View Article and Find Full Text PDFPreparing the AI-assisted animal scientist: faculty and student perspectives on enhancing animal science education with artificial intelligence.
Anim Front
December 2024
Department of Animal Science, Iowa State University, Ames, Iowa 50011, USA.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!